{"name":"Suzhou Zanrong Pharma Limited","slug":"suzhou-zanrong-pharma-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOdkt1MGZKVUp0VDFnb29EYmNoNkhVX3VTOTN3R1NJMXdBVXJSVnJPbWdIRWJIamFETmFGQmdRZEJnT1prOVdkbHhEY0Q4RDRHMDFRUGp6WktDQzdheEVWUElqUVU3OHhtcjQwTFFNOXFLYlFiMTNSSEVtNVp1ckNqVkVR?oc=5","date":"2023-05-10","type":"deal","source":"Pharmaceutical Technology","summary":"Roche buys worldwide rights to Zion Pharma’s ZN-A-1041 - Pharmaceutical Technology","headline":"Roche buys worldwide rights to Zion Pharma’s ZN-A-1041","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPd1dDOWZ4ZlZBbUpxTl9RQ2NRRl9TcFJjcXVpYVRjUkFLT2xZM1pacF9XdTQ3RmJ1RG5Feko0S0dPN3pHTTc3aGhMRXFKem50VkFDd0VYUGlCMTJoU0FIZnJ0M2pJMzd1N1BuSWFGaE9RWUVLU09YUk5HTnhyOV9PUW1SVlZ4em5aaDJDMlVlcTFUNFZIZkhHX0lrYzc0ZTg1eDRscEpn?oc=5","date":"2023-05-09","type":"deal","source":"BioWorld News","summary":"Zion Pharma in $680M Roche deal for its HER2 breast cancer drug - BioWorld News","headline":"Zion Pharma in $680M Roche deal for its HER2 breast cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNOTRwNkJCQWJJZkp5eGVSZzJtakZsbTVNMnlOcUFkZVpsakZINlNEbFV2XzctOFp6MFh1T0VsNTBQUUo2SzN0Q3k2by0tRndWZDRwbDBleVFpRWx5WEpkNXYxQlFwTXJvdVZhaXRlZko0VGZnaTFvYXcyZzZxb3E1MUx4MXl2ZlNWZjNKQm0wbjRBZ3hfWGRKVXZmTHpZZVF5YXFDSGdaSFNkdXFHQ2E2X3pMZmhydEFrZGRSQXlfRGJOMWZoODlJbjVXVW9QbFJuUEc0cldSR2ViY0tEa2hrbGhHYVFlMHctZWY4UDBGTE1fOUhvVkNRRkVsUVNpcmZwY0lXUEtfRzRtSVExZ05ZZWtUYnE0Mm10TFU4aUN4X0NPQS1hdGV4b0VvRQ?oc=5","date":"2023-05-09","type":"pipeline","source":"Business Wire","summary":"Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor - Business Wire","headline":"Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPa1lFb0ZLd1dpSFQwYTdQSE8tb2RTeXdHaFBWWWtaSXM4ZktDWHdCcDdLYUhsUGFQOWQyMzl4RjAwbWVfdW92Vk1GT3BLYkdQYk52azh2U2JLNjFPd3dac0hCWVVINkljUUxWd0JrdXh2LTBXS0lkQVJnZDMwcDdsbG9GOXFBRktKTkVOb2p6cWVOR0NXcS1nVlZmN3kycFB6dW1heUJmejZidGcta21PS2JpQU5IUkxrTHlBM3kyZw?oc=5","date":"2023-05-09","type":"pipeline","source":"Fierce Biotech","summary":"Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect - Fierce Biotech","headline":"Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}